Aprotinin
A 58-residue bovine serine protease inhibitor approved by the FDA in 1993 as Trasylol to reduce bleeding in coronary bypass surgery, suspended in 2007 after the BART trial, relicensed in Canada and Europe, and still used in US fibrin sealants.
Also referenced as: Trasylol, BPTI, Bovine pancreatic trypsin inhibitor, Basic pancreatic trypsin inhibitor, BAYA0128
Also appears in: Other
Public product evidence No certificate records are bound to a tracked Aprotinin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Aprotinin product pages. Other certificates naming this compound may still exist — search the wider certificate database.This compound maps to at least one regulated medical product or label context in the United States.
Primary research area: Cardiovascular. Also surfaces under Other for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Trasylol, BPTI, Bovine pancreatic trypsin inhibitor, Basic pancreatic trypsin inhibitor, BAYA0128
No FDA label signal · 62 trials · 1000 PubMed results
Aprotinin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Aprotinin has 18 name-matched clinical trials (1 international) (highest phase: Phase 3) and 1000 PubMed-indexed publications and holds an FDA drug label. Human trials are registered but none have posted results yet. Note: 12 retracted publications in the literature.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Aprotinin?
Aprotinin is a small protein rather than a synthetic peptide: a single polypeptide chain of 58 amino acids cross-linked by three disulfide bridges, with the empirical formula C284H432N84O79S7 and a molecular weight of 6,512 daltons, obtained from bovine lung according to the US label. It was first characterized as the basic trypsin inhibitor of bovine pancreas; the full 58-residue sequence was reported in 1965 (Kassell et al., Biochemical and Biophysical Research Communications, 1965;18:255–258) and the crystal structure in 1970 (Huber et al., Naturwissenschaften, 1970;57(8):389–392), making it the prototype of the Kunitz domain family that also includes the engineered kallikrein inhibitor ecallantide. Biochemists call it bovine pancreatic trypsin inhibitor (BPTI); in medicine it is aprotinin, sold by Bayer as Trasylol and measured in kallikrein inhibitor units (KIU), with 10,000 KIU equal to 1.4 mg.
The FDA approved Trasylol on December 29, 1993 for coronary artery bypass graft (CABG) patients at increased risk of blood loss. Bayer announced a temporary suspension of worldwide marketing on November 5, 2007 after the BART trial was stopped, and the drug was later relicensed in Canada and the European Union but not in the US, where aprotinin now appears only as the synthetic fibrinolysis inhibitor in Baxter’s Tisseel and Artiss fibrin sealants.
How it works
- Canonical Kunitz-type inhibition. Aprotinin is a reversible, tight-binding inhibitor that presents an exposed loop to the protease active site; the crystal structure of its complex with bovine trypsin, refined at 1.9 Å, showed the reactive-site lysine occupying the enzyme’s substrate pocket in a substrate-like but uncleaved arrangement (Huber et al., Journal of Molecular Biology, 1974;89(1):73–101). The same mechanism covers trypsin, chymotrypsin, plasmin and tissue and plasma kallikreins (Fritz and Wunderer, Arzneimittel-Forschung, 1983;33(4):479–494).
- Antifibrinolytic and anti-inflammatory action during bypass. The US label describes aprotinin as modulating the systemic inflammatory response to cardiopulmonary bypass: inhibiting kallikrein and plasmin attenuates fibrinolysis, thrombin generation and inflammatory activation, reduces loss of the platelet glycoproteins GpIb and GpIIb/IIIa, and prevents granulocyte expression of the adhesion glycoprotein CD11b.
- Platelet protection through protease-activated receptor 1. In washed human platelets, 50 to 160 KIU/mL inhibited thrombin-induced aggregation by 42.6 to 86.6% while leaving responses to collagen, epinephrine and ADP intact; because the non-proteolytic PAR1 agonist peptide SFLLRN was unaffected, the effect was attributed to preventing thrombin from cleaving PAR1 (Poullis et al., Journal of Thoracic and Cardiovascular Surgery, 2000;120(2):370–378). That selectivity is the proposed explanation for a hemostatic drug with antithrombotic effects (Landis et al., Annals of Thoracic Surgery, 2001;72(6):2169–2175).
- Pharmacokinetics and antiviral protease inhibition. The label reports rapid distribution after intravenous injection, a plasma half-life of about 150 minutes, a terminal half-life of about 10 hours, and renal handling similar to other small proteins such as insulin, with about 2% of a 1 million KIU infusion excreted unchanged. Because respiratory viruses depend on host serine proteases to activate their surface glycoproteins, aprotinin suppresses influenza hemagglutinin cleavage (Zhirnov et al., Antiviral Research, 2011;92(1):27–36) and inhibited SARS-CoV-2 replication in cell culture at therapeutically achievable concentrations (Bojkova et al., Cells, 2020;9(11):2377).
Research status
Early trials and approval. High-dose use began with a 22-patient randomized trial of repeat open-heart surgery: mean blood loss was 286 mL with aprotinin versus 1,509 mL in controls (p<0.001), and transfusion requirements were eightfold higher in controls (Royston et al., Lancet, 1987;2(8571):1289–1291). In the placebo-controlled CABG trials summarized in the US label, patients treated with aspirin within 48 hours of surgery lost a mean of 1,209.7 mL of blood versus 2,532.3 mL and received 1.6 versus 4.3 units of red cells.
Randomized evidence base. The 2011 Cochrane review pooled 252 randomized trials with more than 25,000 participants. Against control, aprotinin cut red cell transfusion by 34% (RR 0.66, 95% CI 0.60–0.72) and re-operation for bleeding by 54% (RR 0.46, 95% CI 0.34–0.62) and did not increase myocardial infarction, stroke, renal dysfunction or mortality (RR 0.81, 95% CI 0.63–1.06); in head-to-head trials against tranexamic acid and aminocaproic acid, however, it carried a higher risk of death (RR 1.39, 95% CI 1.02–1.89), driven mostly by BART (Henry et al., Cochrane Database of Systematic Reviews, 2011;(3):CD001886).
Observational safety signals, 2006 to 2008. In a prospective cohort of 4,374 revascularization patients, propensity-adjusted aprotinin use was associated with a doubling of dialysis-requiring renal failure (odds ratio 2.59 in complex and 2.34 in primary surgery), a 55% increase in myocardial infarction or heart failure and a 181% increase in stroke or encephalopathy, none of which appeared with the lysine analogues (Mangano et al., New England Journal of Medicine, 2006;354(4):353–365). Five-year follow-up of 3,876 of these patients found 20.8% mortality with aprotinin versus 12.7% with no agent, adjusted hazard ratio 1.48 (Mangano et al., JAMA, 2007;297(5):471–479), and an administrative analysis of 33,517 aprotinin and 44,682 aminocaproic acid recipients found in-hospital death in 4.5% versus 2.5%, adjusted relative risk 1.64 (Schneeweiss et al., New England Journal of Medicine, 2008;358(8):771–783). The November 2006 US label added a boxed warning on fatal anaphylaxis and a renal dysfunction warning.
BART and the suspension. The Canadian Blood Conservation Using Antifibrinolytics in a Randomized Trial enrolled 2,331 high-risk cardiac surgery patients (781 aprotinin, 770 tranexamic acid, 780 aminocaproic acid) and was stopped early. Massive postoperative bleeding occurred in 9.5% with aprotinin versus 12.1% with each comparator (RR 0.79, 95% CI 0.59–1.05), but 30-day mortality was 6.0% versus 3.9% and 4.0%, a relative risk of 1.53 (95% CI 1.06–2.22) against the pooled lysine analogues (Fergusson et al., New England Journal of Medicine, 2008;358(22):2319–2331). Bayer suspended worldwide marketing on November 5, 2007 at the request of the FDA and other regulators, the Cochrane authors date the withdrawal from world markets to May 2008, and US access then ran only through an FDA-approved treatment protocol for high-risk CABG patients (NCT00611845), now listed as no longer available.
Reassessment and relicensing abroad. Health Canada recommended approval of aprotinin with warnings in September 2011 and requested further safety studies in high-risk patients. In February 2012 the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended lifting the EU suspension, judging the BART results unreliable because of imbalances in heparin use, inappropriate monitoring of anticoagulation and exclusion of some patients from the initial analysis, and concluding that benefits exceeded risks in isolated CABG at high risk of major blood loss, subject to a heparin warning and an EU registry. The BART investigators disputed that reading in “Regulatory decisions pertaining to aprotinin may be putting patients at risk” (Hébert et al., CMAJ, 2014;186(18):1379–1386). The Nordic Group became the marketing-authorization holder for Trasylol outside the US (relicensing reviewed in Royston et al., Anaesthesia Critical Care & Pain Medicine, 2017;36(2):97–102).
Post-authorization registry. The EMA-mandated Nordic Aprotinin Patient Registry enrolled 5,309 patients from 83 European centers between 2016 and 2020; only 25.7% underwent isolated CABG, the licensed indication. In-hospital mortality was 1.3% in isolated CABG and 8.3% in other surgery, and 12 hypersensitivity reactions (0.2%) were reported (De Hert et al., European Journal of Anaesthesiology, 2022;39(8):685–694). A post hoc analysis of 6,664 registry patients found less re-exploration for bleeding with full-dose than half-dose aprotinin (3.2% versus 4.4%, OR 0.70, p=0.015), no difference in 7-day mortality or major cardiac and cerebral events, and more day-1 acute kidney injury with full dosing in patients with pre-existing renal dysfunction (Colson et al., European Journal of Cardio-Thoracic Surgery, 2025;67(9):ezaf260).
Respiratory antiviral program. A double-blind randomized phase 3 trial of inhaled aprotinin added to standard care for COVID-19 in four Spanish hospitals reported hospital stays 5 days shorter (p=0.003) and a discharge hazard ratio of 2.19 (95% CI 1.18–4.05), with no adverse reactions attributed to the drug (Redondo-Calvo et al., European Journal of Clinical Investigation, 2022;52(6):e13776). A multicenter, double-blind, placebo-controlled phase 3 trial of inhaled aprotinin in acute respiratory distress syndrome, planned for 156 participants, started June 18, 2026, with primary completion estimated for March 1, 2030 (NCT07317050). As of November 2026, no US-directed aprotinin program is registered.
Common dosage forms
- Trasylol solution for intravenous infusion, 10,000 KIU/mL (1.4 mg/mL). The US presentation was 100 mL vials of 1,000,000 KIU and 200 mL vials of 2,000,000 KIU, administered by anesthesiology teams; it is no longer marketed in the US and is sold abroad under the Nordic Group’s authorizations.
- Fibrin sealant component. Tisseel and Artiss (Baxter) contain synthetic aprotinin at 3,000 KIU/mL as the fibrinolysis inhibitor in their sealer protein solution, supplied as frozen pre-filled dual-chamber syringes or, for Tisseel, a freeze-dried kit.
- Inhaled aerosol. A nebulized aprotinin solution is investigational in Spanish trials and has no US-approved presentation.
Key considerations
- Regulatory status. The FDA Approved status reflects the December 29, 1993 approval of Trasylol (aprotinin injection) under application 020304 for prophylactic reduction of perioperative blood loss and transfusion in patients undergoing cardiopulmonary bypass during coronary artery bypass graft surgery who are at increased risk. Bayer suspended worldwide marketing in November 2007 after BART and withdrew the remaining US supply in 2008, Drugs@FDA lists the application as Discontinued rather than withdrawn, and the only aprotinin now on the US market is the synthetic fibrinolysis inhibitor in Baxter’s Tisseel and Artiss fibrin sealants.
- Two regulators read the same trial differently. The EMA judged BART unreliable and relicensed aprotinin in 2012 for isolated CABG at high risk of major blood loss under registry surveillance, Health Canada reinstated it with warnings in 2011, and the product has not returned to the US. The BART investigators maintain their mortality finding, so the net effect on survival in high-risk surgery remains contested.
- Randomized and observational data disagree on harm. Pooled placebo-controlled trials show no excess of death, stroke or renal dysfunction, whereas the large observational cohorts and the head-to-head trials against lysine analogues point to higher mortality and dialysis-requiring renal failure, with renal risk concentrated in patients with pre-existing impairment.
- Anaphylaxis on re-exposure is the defining safety limit. Across 12,403 exposures at one German center, hypersensitivity reactions occurred in 0.09% after first exposure but 1.5% after re-exposure, reaching 4.1% when the interval was under 6 months (Dietrich et al., Annals of Thoracic Surgery, 2007;84(4):1144–1150). Prior exposure includes fibrin sealants containing aprotinin, and the US label contraindicates re-exposure within 12 months.
- Identity and naming. Aprotinin, BPTI, bovine or basic pancreatic trypsin inhibitor and Trasylol denote the same 58-residue Kunitz-domain protein; BAYA0128 is Bayer’s development code, and the Baxter sealants use a synthetic rather than bovine-derived form. It is a protein therapeutic and a routine laboratory protease inhibitor reagent, not a research-market peptide.